| Literature DB >> 27069139 |
Marc-Antoine Bazin1, Bénédicte Rousseau2, Sophie Marhadour1, Christophe Tomasoni2, Pierre Evenou1, Sylvie Piessard1, Abraham J Vaisberg3, Sandrine Ruchaud4, Stéphane Bach4, Christos Roussakis2, Pascal Marchand5.
Abstract
A series of (imidazo[1,2-a]pyrazin-6-yl)ureas were synthesized through 6-aminoimidazo[1,2-a]pyrazine as a key intermediate. 1-(Imidazo[1,2-a]pyrazin-6-yl)-3-(4-methoxy - phenyl)urea displayed a cytostatic activity against a non-small cell lung cancer cell line and was chosen for further mechanistic studies. Growth kinetics highlighted a selective dose-dependent response of P53-mutant NSCLC-N6-L16 cell line and overexpression of TP53 gene induced by this compound. These pharmacological data suggest a promising reactivation of p53 mutant in NSCLC-N6-L16 cell line. CopyrightEntities:
Keywords: Imidazo[1,2-a]pyrazine; NSCLC; antiproliferative activity; p53; urea
Mesh:
Substances:
Year: 2016 PMID: 27069139
Source DB: PubMed Journal: Anticancer Res ISSN: 0250-7005 Impact factor: 2.480